SEATTLE, April 24, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP), developer of the DehyraTECH™ platform for improving the bioavailability of active pharmaceutical ingredients (APIs). The company recently unveiled positive results from its trials involving nicotine, which could pave the way for its entry into the large and growing nicotine replacement industry.
Tobacco use is the leading cause of preventable disease, disability, and death in the United States, according to the CDC, and the same is true for many developed countries. About 40 million Americans still smoke cigarettes and nearly a half a million Americans die prematurely of smoking or exposure to secondhand smoke every year. These trends have given rise to a large and growing smoking cessation industry that could be worth upwards of $20 billion.
A Large & Growing Market
Smoking may be on the decline across many developed countries, but addiction is rapidly increasing in emerging markets. A growing body of evidence has shown that smoking causes diseases like chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, which translates to a high mortality rate. These trends have led to strong demand for innovative nicotine replacement therapy products to help smokers kick the habit.
According to Grand View Market Research, the smoking cessation and nicotine de-addiction market is projected to reach $21.8 billion in size by 2024. These products include nicotine chewing gums and transdermal patches, as well as e-cigarettes, which are projected to see a 19 percent compound annual growth rate over the forecast period. North America represents the largest market with a 35 percent share, but the Asia-Pacific region is the fastest growing market.
There are many different public companies active in the space, including Pfizer Inc. (PFE), GlaxoSmithKline plc (GSK), and Imperial Tobacco Ltd. (IMBBY), which have developed established gum and patch products. Smaller companies have been largely active in the e-cigarette space given the heightened regulatory risk, although this segment remains one of the fastest growing subsets of the nicotine replacement industry.
Lexaria’s Breakthrough
Lexaria Bioscience recently announced positive top-line results upon completion of its first ingestible nicotine in vivo absorption study using its DehydraTECH™ technology. The highlights of the study include a 1,160 percent faster delivery of equivalent peak quantities of nicotine into the bloodstream (15 minutes vs. 2.9 hours) and lower quantities of key liver metabolites in the bloodstream, suggesting bypass of first pass liver metabolism.
The company’s formulations achieved faster absorption, higher peak absorption, and higher overall quantities of nicotine, on average, in the blood than the concentration-matched control formulations at both 1mg and 10mg per kilogram doses. Furthermore, there were no obvious signs of gastrointestinal distress, such as vomiting or diarrhea, suggesting that treatment options incorporating the technology would be both safe and effective.
“We are very pleased with these topline study findings demonstrating excellent tolerability and substantially faster, more potent and bioavailable absorption of nicotine in an ingestible format with our DehydraTECH™ technology than controls,” said Lexaria President John Docherty. “This data supports further investigation of the many possible benefits of our DehydraTECH™ technology for nicotine delivery with potential both as a nicotine replacement therapy, as well as an alternative product format for regular tobacco users over today’s inhaled options.”
The company’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredients (APIs), such as nicotine. It provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. As such, the company’s long-term strategy is to partner with leading firms to deliver best-of-class products to existing customers. These topline results with nicotine could open the door to such partnerships with leading nicotine replacement firms.
Looking Ahead
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) represents a compelling investment opportunity in the biopharmaceutical industry. With its innovative DehydraTECH™ technology, the company is able to improve the bioavailability of a wide range of APIs, which creates a significant opportunity for licensing and partnerships. The most recent results with nicotine could open the door to a $21.8 billion industry that’s ripe for innovation.
For more information, visit the company’s website or download their investor presentation.
Please follow the link to read the full article: http://www.cannabisfn.com/lexaria-achieves-breakthrough-21-8-billion-smoking-cessation-industry/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
Frank Lane
206-369-7050
Flane@cannabisfn.com